Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6794996 | 1.00 | MAPKAPK2 (0.33) | MAPKAPK2RAD52UBE2NL3MBTL1MLYCD | |
| Trifluoroacetic Acid SCHEMBL6795299 | 0.94 | KCNH2 (0.37) | MAPKAPK2RAD52UBE2NL3MBTL1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL6795303 | 0.94 | KCNH2 (0.37) | MAPKAPK2RAD52UBE2NL3MBTL1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL6792665 | 0.94 | MAPKAPK2 (0.40) | MAPKAPK2RAD52UBE2NL3MBTL1MLYCD | |
| Trifluoroacetic Acid SCHEMBL6792669 | 0.94 | MAPKAPK2 (0.40) | MAPKAPK2RAD52UBE2NL3MBTL1MLYCD | |
| Trifluoroacetic Acid SCHEMBL4255917 | 0.89 | MAPKAPK2 (0.30) | MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL4255911 | 0.89 | MAPKAPK2 (0.30) | MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL4256992 | 0.89 | MAPKAPK2 (0.36) | MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL4256994 | 0.89 | MAPKAPK2 (0.36) | MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL6792657 | 0.87 | ALK (0.46) | KCNH2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885RAD52 4360/4885UBE2N 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.